Ustekinumab-Aauz

Collaboration provides direct access to three competitively priced biosimilars through a transparent pricing model across immunology and inflammatory diseases CHICAGO and LAKE ZURICH, Ill, Sept. 29, 2026 /PRNewswire/ -- Waltz Health®, an EVERSANA® company developing technologies and services that support better-informed decisions on prescription care and Fresenius Kabi®, an operating company of Fresenius, and a leading provider of essential medicines and medical technologies, today announced an agreement to provide employers, payers and pharmacy benefit managers (PBMs) with direct access to three competitively priced biosimilars. The agreement includes the following Fresenius Kabi biosimilars: adalimumab-aacf, a biosimilar to Humira®; Otulfi® (ustekinumab-aauz), a biosimilar to Stelara® and Tyenne® (tocilizumab-aazg), a biosimilar to Actemra.1 As biopharma is a key growth area for the company, the agreement supports Fresenius Kabi's approach to expand access to high-quality, affordable biological therapies in the U.S. through innovative commercial partnerships. The launch expands Waltz Health's Direct-to-Payer program within the Waltz Connect platform to include additional specialty therapeutic areas, building on its recent rollout of direct access to anti-obesity GLP-1 medications. "Employers and payers are looking for new ways to access specialty medications at transparent, sustainable prices," said Jeff Park, President of Waltz Health. "By expanding into biosimilars, Waltz is opening a new pathway for manufacturers to work directly with employers and health plans while giving patients access to high-quality biosimilar therapies through a more transparent and cost-efficient model." "Biosimilars continue to demonstrate their value in lowering the cost of biologic medicines in the United States while providing access for patients to high-quality products," said Dr. Sang-Jin Pak, President of Biopharma at Fresenius Kabi. "As we continue to expand our biosimilars portfolio, we remain focused on innovative partnerships that help employers and payers access high-quality treatment options. Our collaboration with Waltz Health is a strong example of how we can work together to improve access for patients." Competitive Pricing for High-Cost Specialty Categories The partnership introduces transparent contract pricing designed to help commercial plans manage the cost of care across three major inflammatory disease categories, rheumatology, dermatology, and gastroenterology2. Adalimumab-aacf, the Humira biosimilar, is a medication commonly used across a range of autoimmune conditions and competes with therapies within the anti-TNF and related immunology drug classes. Otulfi, the Stelara biosimilar, provides employers and payers with a lower-cost alternative across therapies commonly used to treat certain autoimmune conditions such as psoriasis and inflammatory bowel disease. Tyenne, the Actemra biosimilar, supports treatment access for patients with certain conditions including rheumatoid arthritis and other inflammatory diseases. Plan members will have access to these biosimilars offered through a transparent pricing model with a clearly defined price per unit. This structure enables Waltz Health to offer consistent, predictable pricing while improving access to biologic therapies. Waltz Health applies a transparent, previously disclosed flat fee, with the final cost to the employee or member varying based on individual pharmacy fees and each plan sponsor's benefit design. Expanding Waltz Health's Direct-to-Payer Program Waltz Health's Direct-to-Payer Programs connect employers, payers and other plan sponsors directly with pharmaceutical manufacturers through a transparent model, powered by the technology-enabled Waltz Connect platform. The programs allow manufacturers to offer medications at pre-negotiated prices without relying on traditional rebate structures, creating a direct pathway between manufacturers and plan sponsors. Under the program, employers or other plan sponsors contract with Waltz Health to offer eligible medications to their covered members at transparent prices. Employees who receive prescriptions for participating therapies access those medications through the Waltz Connect process, where eligibility and pricing are verified before fulfillment. Fulfillment models within Waltz Connect are designed around the needs of each manufacturer partnership. For this collaboration with Fresenius Kabi, prescriptions will be filled through a dedicated specialty pharmacy operated by EVERSANA and delivered directly to patients' homes through a specialty pharmacy distribution model. The arrangement reflects Waltz Health's expanding integration with EVERSANA's integrated commercialization platform, combining Waltz's marketplace and contracting capabilities with EVERSANA's pharmacy infrastructure and manufacturer services to support direct access programs at scale. By bypassing traditional wholesaler distribution and rebate-driven PBM channels, the Waltz Connect model reduces intermediary costs while maintaining the clinical support and patient services typically associated with specialty pharmacy. About Waltz Health Waltz Health, an EVERSANA company, is a digital health company developing technologies and services that support better-informed decisions on prescription care. Designed for payers, pharmacies, pharmacy benefit managers and self-insured employers, the company offers AI-driven marketplaces to lower overall drug costs, providing better pricing options and more information for consumers, while also helping payers take control of their pharmacy benefits. For more information, visit . About Fresenius Kabi Fresenius Kabi is part of the global healthcare company Fresenius and specializes in lifesaving medicines, medical technologies, and services for critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's broad portfolio enables access to high-quality products across emergency medicine, surgery, oncology, intensive care, and at home – reaching around 450 million patients each year. Through complementary business areas, Fresenius Kabi offers highly complex biopharmaceuticals for the treatment of cancer, autoimmune and endocrine diseases; leading enteral, parenteral and homecare solutions within medical nutrition; innovative medical technology including infusion pumps, cell and gene therapy devices, disposables and blood collection systems; and intravenous generic drugs and fluids that are vital to the work of healthcare providers globally. For more information, please visit . About Fresenius Fresenius (XFRA: FRE, OTC: FSNUY) is a global, therapy-focused healthcare company dedicated to saving and improving human lives around the world. Through Fresenius Kabi and Fresenius Helios, the company delivers system-critical, innovative and affordable healthcare across the full continuum of care: Fresenius Kabi is a leading provider of lifesaving medicines, clinical nutrition, and medical technologies for critically and chronically ill patients, reaching around 450 million people each year. Fresenius Helios is Europe's largest private hospital operator, treating around 27 million patients annually. With more than 178,000 employees and operating in more than 60 countries, Fresenius generated €22.6 billion in revenue in 2025. For more information, visit  and follow Fresenius on LinkedIn. This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release. For Waltz Health Sam Moore 225-931-4081 [email protected] SOURCE Waltz Health 21% more press release views with Request a Demo

Nonprofit pharmaceutical company has delivered nearly $44 million in savings since 2022 LEHI, Utah, June 25, 2026 /PRNewswire/ -- CivicaScript's transparent, nonprofit business model saved patients and payer members more than $16 million in 2025 after they switched to its low-cost generic medicines, the company's new Annual Savings Report shows. Patients saved as much as 91% per claim. Since the launch of its first product in 2022, CivicaScript has delivered nearly $44 million in savings to patients and its payer members. The 2025 savings were driven by CivicaScript's first product, abiraterone acetate tablets USP, 250 mg, and four additional specialty generics launched that year. The new report shows that while conversion to CivicaScript's newer products is still in early stages, the products are already driving significant per claim savings. Meanwhile, the continued growth of CivicaScript abiraterone (now sold under the proprietary name Abirtega®) underscores the ongoing need for the company's unique business model. "CivicaScript was created to bring affordability and transparency to the generic and biosimilar drug market," said CivicaScript President Brent J. Eberle. "This report demonstrates the substantial savings that can be achieved when manufacturers, payers and pharmacies work together to put patients first." CivicaScript expects savings to continue to grow as additional products gain adoption and its new therapies enter the market. Earlier this year, the organization expanded into biosimilars with the launch of a low-cost private-label insulin glargine and exclusive distribution of ustekinumab-aauz,1 a biosimilar to Stelara®2. Civica insulin is available nationwide; in California, it is sold under the CalRx®3 brand. Key 2025 savings data Patients who used CivicaScript medicines in 2025 saved more than $400,000 in out-of-pocket pharmacy costs. Per claim savings varied by product and product strength; the highest average per claim savings for patients was $56 (for droxidopa capsules, 300 mg). CivicaScript payer members, who bear a larger share of total medicine costs, saw $15.7 million in savings in 2025. On average, payers saved $856/claim with abiraterone – the company's most utilized product -- and $80/claim to $2,358/claim for its four newer products. CivicaScript is a nonprofit pharmaceutical company created in 2020 to lower the prices of prohibitively expensive generic medicines. The company's business model is to manufacture low-cost generic medicines, then work with payers, PBMs and pharmacies across the country to pass along the cost savings to patients. The model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient. CivicaScript's MaxRP® policy is its maximum recommended price to the consumer. Information on every CivicaScript product package enables healthcare providers, caregivers, patients and others to compare prices and confirm they are being charged no more than the MaxRP. "At a time when too many families are facing rising prescription drug costs, our partnership with CivicaScript is delivering on a simple, but powerful, promise to make essential generic medicines more affordable," said Sean Robbins, EVP and Chief Operating Officer at Blue Cross Blue Shield Association. "By advancing a transparent model that puts patients first, we're helping reshape the marketplace to bring more competition, lower costs and improve access for the people who need these medicines most." About the analysis The report analyzed pharmacy claims data from January 1 through December 31, 2025, from each CivicaScript member. The report reflects the savings from CivicaScript products as of their first full quarter of availability. 1 Ustekinumab-aauz injection, 45 mg/0.5mL and 90 mg/mL 2 Stelara® is a registered trademark of Johnson & Johnson. 3 CalRx® is a registered trademark of the California Department of Health Care Access and Information. SOURCE Civica Rx 21% more press release views with Request a Demo